MANTRA CAPITAL Q2 FY27
Net Profit: βΉ1.82 Cr vs βΉ3.21 Cr loss YoY | vs βΉ3.96 Cr loss QoQ
NII: βΉ2.48 Cr β45% YoY | β7% QoQ
Net Profit: βΉ1.82 Cr vs βΉ3.21 Cr loss YoY | vs βΉ3.96 Cr loss QoQ
NII: βΉ2.48 Cr β45% YoY | β7% QoQ
Indian Overseas Bank β Q2 FY27 FINANCIAL RESULTS HIGHLIGHTS
Financial results for the quarter and half-year ended 30th September 2026:
- Net Profit for Q2 FY27 increased 55.95% YoY to INR 1912 Cr
- Net Interest Income for Q2 FY27 increased 26.41% YoY to INR 3867 Cr
- Operating Profit for Q2 FY27 increased 25.67% YoY to INR 3016 Cr
- Gross NPA ratio reduced to 1.19% and Net NPA ratio reduced to 0.16%
- Global Business increased 22.05% YoY to INR 753078 Cr
- H1 FY27 Net Profit increased 52.85% YoY to INR 3572 Cr
Financial results for the quarter and half-year ended 30th September 2026:
- Net Profit for Q2 FY27 increased 55.95% YoY to INR 1912 Cr
- Net Interest Income for Q2 FY27 increased 26.41% YoY to INR 3867 Cr
- Operating Profit for Q2 FY27 increased 25.67% YoY to INR 3016 Cr
- Gross NPA ratio reduced to 1.19% and Net NPA ratio reduced to 0.16%
- Global Business increased 22.05% YoY to INR 753078 Cr
- H1 FY27 Net Profit increased 52.85% YoY to INR 3572 Cr
β€2π₯1
LUMAX INDUSTRIES Q2 FY27 (CONS.)
Net Profit: βΉ51.99 Cr β45.87% YoY | β1.78% QoQ
Revenue: βΉ1,341.84 Cr β33.04% YoY | β9.70% QoQ
EBITDA: βΉ115.62 Cr β30.41% YoY | β7.32% QoQ
EBITDA Margin: 8.62% vs 8.79% YoY | 8.81% QoQ
Net Profit: βΉ51.99 Cr β45.87% YoY | β1.78% QoQ
Revenue: βΉ1,341.84 Cr β33.04% YoY | β9.70% QoQ
EBITDA: βΉ115.62 Cr β30.41% YoY | β7.32% QoQ
EBITDA Margin: 8.62% vs 8.79% YoY | 8.81% QoQ
SupremeInd Mgmt On CNBC-TV18 Says:
β©Volume Growth In FY27 Will Be 10%
β©Overall Volume Growth In FY27 Will Be 10% Vs 12% Guided Earlier
β©Q3FY27 Has Started On A Strong Footing
β©Margin Will Hold Around 14-14.5% In FY27
β©Piping Volume Guidance Expected At 13% In FY27 Vs 15% Earlier
β©Volume Growth In FY27 Will Be 10%
β©Overall Volume Growth In FY27 Will Be 10% Vs 12% Guided Earlier
β©Q3FY27 Has Started On A Strong Footing
β©Margin Will Hold Around 14-14.5% In FY27
β©Piping Volume Guidance Expected At 13% In FY27 Vs 15% Earlier
β€1
ATHER ENERGY Q2 FY27 (STANDALONE)
Net Profit: βΉ4 Cr vs βΉ157 Cr loss YoY | vs βΉ51 Cr loss QoQ
Revenue: βΉ1,464 Cr β63% YoY | β20% QoQ
Other Income: βΉ63 Cr vs βΉ42 Cr YoY | βΉ43 Cr QoQ
EPS: βΉ0.04 vs -βΉ4.11 YoY | -βΉ1.33 QoQ
Net Profit: βΉ4 Cr vs βΉ157 Cr loss YoY | vs βΉ51 Cr loss QoQ
Revenue: βΉ1,464 Cr β63% YoY | β20% QoQ
Other Income: βΉ63 Cr vs βΉ42 Cr YoY | βΉ43 Cr QoQ
EPS: βΉ0.04 vs -βΉ4.11 YoY | -βΉ1.33 QoQ
β€3
SRM CONTRACTORS LIMITED: CO. BAGS CONTRACT WORTH βΉ138.37 CRORES FROM MORTH FOR LANDSLIDE TREATMENT ON NH-09; CONTRACT TO BE EXECUTED IN 18 MONTHS.
JBMA: Q2 CONS NET PROFIT 586M RUPEES VS 526M (YOY)
JBMA: Q2 EBITDA 1.9B RUPEES VS 1.55B (YOY); Q2 EBITDA MARGIN 11.54% VS 11.33% (YOY)
JBMA: Q2 REVENUE 16.6B RUPEES VS 13.7B (YOY)
JBMA: Q2 EBITDA 1.9B RUPEES VS 1.55B (YOY); Q2 EBITDA MARGIN 11.54% VS 11.33% (YOY)
JBMA: Q2 REVENUE 16.6B RUPEES VS 13.7B (YOY)
ATHER ENERGY: BOARD APPROVES EXPANSION OF MANUFACTURING CAPACITY; CAPEX OF βΉ122 CRORES ALLOCATED; HOSUR CAPACITY TO INCREASE FROM 420,000 TO 495,000 UNITS; FACTORY 3.0 CAPACITY TO RISE FROM 500,000 TO 650,000 UNITS; COMPLETION EXPECTED BY DECEMBER 2026 AND Q2 FY28
π2
AVANTEL Q2 FY27
Net Profit: βΉ7 Cr β60% YoY | β26% QoQ
Revenue: βΉ74 Cr β34% YoY | β6% QoQ
Other Income: βΉ0 Cr vs βΉ1 Cr YoY | βΉ0 Cr QoQ
Operating Profit: βΉ21 Cr β84% YoY | β20% QoQ
Operating Profit Margin: 28.0% vs 20.4% YoY | 24.8% QoQ
EPS: βΉ0.26 β73% YoY | β30% QoQ
Net Profit: βΉ7 Cr β60% YoY | β26% QoQ
Revenue: βΉ74 Cr β34% YoY | β6% QoQ
Other Income: βΉ0 Cr vs βΉ1 Cr YoY | βΉ0 Cr QoQ
Operating Profit: βΉ21 Cr β84% YoY | β20% QoQ
Operating Profit Margin: 28.0% vs 20.4% YoY | 24.8% QoQ
EPS: βΉ0.26 β73% YoY | β30% QoQ
π2
ATHER ENERGY: CO WILL FURTHER EXPAND THE PLANTβS ANNUAL CAPACITY BY 1.5 LAKH UNITS TO 6.5 LAKH UNITS, WITH THE ADDITIONAL CAPACITY EXPECTED TO COMMENCE PRODUCTION BY Q2 FY28
π2
MANKIND PHARMA Q2 FY27
Net Profit: βΉ711 Cr β39% YoY | β25% QoQ
Revenue: βΉ4,338 Cr β17% YoY | β8% QoQ
Other Income: βΉ95 Cr vs βΉ92 Cr YoY | βΉ45 Cr QoQ
EPS: βΉ17.23 β39% YoY | β25% QoQ
Net Profit: βΉ711 Cr β39% YoY | β25% QoQ
Revenue: βΉ4,338 Cr β17% YoY | β8% QoQ
Other Income: βΉ95 Cr vs βΉ92 Cr YoY | βΉ45 Cr QoQ
EPS: βΉ17.23 β39% YoY | β25% QoQ
π₯2
MANKIND: Q2 CONS NET PROFIT 7.1B RUPEES VS 5.11B (YOY); EST 6.15B
MANKIND: Q2 EBITDA 11.7B RUPEES VS 9.21B (YOY); Q2 EBITDA MARGIN 27% VS 24.92% (YOY)
MANKIND: Q2 REVENUE 43.4B RUPEES VS 36.97B (YOY)
MANKIND: Q2 EBITDA 11.7B RUPEES VS 9.21B (YOY); Q2 EBITDA MARGIN 27% VS 24.92% (YOY)
MANKIND: Q2 REVENUE 43.4B RUPEES VS 36.97B (YOY)
β€2
MILKFOOD Q2 FY27
Net Profit: βΉ1 Cr vs βΉ8 Cr loss YoY | β500% QoQ
Revenue: βΉ101 Cr β37% YoY | β25% QoQ
EBITDA: βΉ6 Cr vs βΉ2 Cr loss YoY | β84% QoQ
EBITDA Margin: 6.3% vs -3.1% YoY | 4.3% QoQ
Net Profit: βΉ1 Cr vs βΉ8 Cr loss YoY | β500% QoQ
Revenue: βΉ101 Cr β37% YoY | β25% QoQ
EBITDA: βΉ6 Cr vs βΉ2 Cr loss YoY | β84% QoQ
EBITDA Margin: 6.3% vs -3.1% YoY | 4.3% QoQ
MANKIND PHARMA Q2 FY27 (CONS.) ; NET PROFIT UP 37.67% AT βΉ716.12 CR (YOY), UP 24.74% (QOQ)
REVENUE UP 17.33% AT βΉ4,337.86 CR (YOY), UP 7.62% (QOQ)
EBITDA UP 27.13% AT βΉ1,171.25 CR (YOY), UP 10.89% (QOQ)
MARGINS AT 27.00% VS 24.92% (YOY), 26.20% (QOQ)
REVENUE UP 17.33% AT βΉ4,337.86 CR (YOY), UP 7.62% (QOQ)
EBITDA UP 27.13% AT βΉ1,171.25 CR (YOY), UP 10.89% (QOQ)
MARGINS AT 27.00% VS 24.92% (YOY), 26.20% (QOQ)
MANKIND PHARMA Q2 FY27 β ACTUAL VS ESTIMATES
Revenue: βΉ4,337.86 Cr vs βΉ4,164.38 Cr est. β BEAT BY 4%
Net Profit: βΉ711.48 Cr vs βΉ619 Cr est. β BEAT BY 15%
EPS: βΉ17.23 vs βΉ15.11 est. β BEAT BY 14%
Revenue: βΉ4,337.86 Cr vs βΉ4,164.38 Cr est. β BEAT BY 4%
Net Profit: βΉ711.48 Cr vs βΉ619 Cr est. β BEAT BY 15%
EPS: βΉ17.23 vs βΉ15.11 est. β BEAT BY 14%
MAHABANK: Q2 SL NET PROFIT 23B RUPEES VS 16.3B (YOY); EST 21B
MAHABANK: Q2 GNPA 1.25% VS 1.45% (QOQ); Q2 NNPA 0.12% VS 0.13% (QOQ)
MAHABANK: Q2 REVENUE 86B RUPEES VS 71B (YOY)
MAHABANK: Q2 GNPA 1.25% VS 1.45% (QOQ); Q2 NNPA 0.12% VS 0.13% (QOQ)
MAHABANK: Q2 REVENUE 86B RUPEES VS 71B (YOY)
β€2
BANK OF MAHARASHTRA Q2 FY27
Net Profit: βΉ2,136 Cr β27.98% YoY | β5.59% QoQ
NII: βΉ3,955 Cr β21.77% YoY | β4.91% QoQ
Operating Profit: βΉ3,369 Cr β30.83% YoY | β8.05% QoQ
Provisions: βΉ654 Cr β22% QoQ
Net Profit: βΉ2,136 Cr β27.98% YoY | β5.59% QoQ
NII: βΉ3,955 Cr β21.77% YoY | β4.91% QoQ
Operating Profit: βΉ3,369 Cr β30.83% YoY | β8.05% QoQ
Provisions: βΉ654 Cr β22% QoQ
DEALING ROOM UPDATES NDTV Profit
ACUTAAS CHEMICALS, CDSL π’
β’ Buying interest on large HNI desks.
β’ Dealers expect strong Q2 earnings.
COAL INDIAπ’
β’ Multiple dealing rooms recommending buy calls to clients.
β’ Strong volume growth expected.
VARUN BEVERAGES, GLENMARK, ADANI POWER π’
β’ Higher delivery volumes seen.
β’ Buying interest on institutional desks.
MARUTI SUZUKIπ»
β’ Selling interest on large HNI and PMS desks.
β’ Dealers expect weak earnings.
SRF π’
β’ Multiple dealing rooms recommending buy calls.
β’ Expected to benefit from import curbs on Chinese products.
ACUTAAS CHEMICALS, CDSL π’
β’ Buying interest on large HNI desks.
β’ Dealers expect strong Q2 earnings.
COAL INDIAπ’
β’ Multiple dealing rooms recommending buy calls to clients.
β’ Strong volume growth expected.
VARUN BEVERAGES, GLENMARK, ADANI POWER π’
β’ Higher delivery volumes seen.
β’ Buying interest on institutional desks.
MARUTI SUZUKIπ»
β’ Selling interest on large HNI and PMS desks.
β’ Dealers expect weak earnings.
SRF π’
β’ Multiple dealing rooms recommending buy calls.
β’ Expected to benefit from import curbs on Chinese products.
β€1
SUMITOMO CHEMICAL INDIA Q2 FY27
Net Profit: βΉ157 Cr β11% YoY | β27% QoQ
Revenue: βΉ907 Cr β2% YoY | β15% QoQ
Other Income: βΉ44 Cr vs βΉ39 Cr YoY | βΉ47 Cr QoQ
Operating Profit: βΉ186 Cr β15% YoY | β20% QoQ
Margin: 20.5% vs 23.4% YoY | 21.9% QoQ
EPS: βΉ3.14 β12% YoY | β27% QoQ
Net Profit: βΉ157 Cr β11% YoY | β27% QoQ
Revenue: βΉ907 Cr β2% YoY | β15% QoQ
Other Income: βΉ44 Cr vs βΉ39 Cr YoY | βΉ47 Cr QoQ
Operating Profit: βΉ186 Cr β15% YoY | β20% QoQ
Margin: 20.5% vs 23.4% YoY | 21.9% QoQ
EPS: βΉ3.14 β12% YoY | β27% QoQ
MUSIC BROADCAST Q2 FY27 (STANDALONE)
Net Profit: βΉ7 Cr vs βΉ7 Cr loss YoY | β28% QoQ
Revenue: βΉ41 Cr β8% YoY | β8% QoQ
EBITDA: βΉ6 Cr vs βΉ5 Cr loss YoY | β31% QoQ
EBITDA Margin: 15.0% vs -14.5% YoY | 20.0% QoQ
Net Profit: βΉ7 Cr vs βΉ7 Cr loss YoY | β28% QoQ
Revenue: βΉ41 Cr β8% YoY | β8% QoQ
EBITDA: βΉ6 Cr vs βΉ5 Cr loss YoY | β31% QoQ
EBITDA Margin: 15.0% vs -14.5% YoY | 20.0% QoQ